Mkt share19 Mar 2018 09:31
Omadacycline(Paratek) seems to offer a lower cost solution with its oral formulations which allows earlier discharge of patients. Also, it shows no sign of nephrotoxicity. With Paratek's distribution capability, would MTFB be able gain a significant market share ?